Pharma

Your Article Summary

See Latest Articles

FDA Approves Cardiac Adhesion Barrier for Pediatric Use
FDA Press Releases , 03/09/09

The U.S. Food and Drug Administration announced its approval of a device that reduces the severity of adhesions in children undergoing open-heart surgery. Repel-CV is a synthetic film barrier inserted over the heart just before a surgeon closes the chest following an open-heart procedure. During the early healing stages, the temporary, absorbable barrier helps reduce the severity of post-surgical adhesions.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Ustekinumab (Stelara): First-in-class human monoclonal antibody approved for treatment of moderate-to-severe plaque psoriasis
Formulary , 12/02/09

Safety concerns slow new drug review and approval processes
Formulary , 12/02/09

Teva Announces The Submission Of A Biologics License Application (BLA) For XM02 For The Treatment Of Chemotherapy-Induced Neutropenia
Teva Pharmaceutical Industries, 12/02/09

 See all of Drug/Product Approvals

Today in Regulatory Issues...keeping you current

Receive free subspecialty "5-minute updates" via email

Mandatory Disclosure of Pharmaceutical Industry-Funded Events for Health Professionals
PLoS Medicine, 12/02/09

FDA drug approval intervals from 1997 to 2006: analysis and comparison during information technology implementation
International Journal of Electronic Healthcare , 12/01/09

Regulatory Update: GSK files Rotarix for prevention of rotavirus in Japan
GlaxoSmithKline, 12/01/09

 See all of Regulatory Issues